Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06593210
PHASE3

RSV Vaccine in Transplant Recipients

Sponsor: University Health Network, Toronto

View on ClinicalTrials.gov

Summary

Adjuvant, non-live RSV vaccine will be administered to adult lung and allogeneic hematopoietic stem cell transplant recipients. The safety and immunogenicity of this intervention will be studied. Blood work will be collected before and after the intervention, to assess humoral and cellular immunity. Participants will be followed for adverse reaction, hospitalization, RSV breakthrough infection, graft rejection or graft versus host disease. This study has Health Canada and UHN REB approval.

Official title: Safety and Immunogenicity of Non-live, Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine in Allogeneic Stem Cell Transplant and Lung Transplant Recipients

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-10-01

Completion Date

2026-03

Last Updated

2025-11-26

Healthy Volunteers

No

Interventions

BIOLOGICAL

Adjuvant, non-live RSV vaccine

One dose of arexvy vaccine to transplant recipients.

Locations (1)

University Health Network

Toronto, Canada